Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003128 (anovulation)
 1,718 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A potent luteinizing hormone-releasing factor (LRF) agonist (D-Trp6-Pro9 NEt)-LRF was studied to determine its effect on pituitary gonadotropin release, and its concomitant ovarian response was examined in normal women during the early follicular (EFP), late follicular (LFP), and midluteal phases (MLP). 16 normal, healthy women volunteered for this study where a single subcutaneous dose of 50 mcg of LRF agonist was injected during the EFP, LFP, and MLP. During the EFP, an injection caused prompt release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) to levels comparable to those of the spontaneous midcycle gonadotropin surge. In LFP subjects, gonadotropin levels rose 1.5-2 times above the midcycle surge level. The LH/FSH release in MLP was almost identical to that found in the EFP. Ovarian response, as measured by increasing estradiol levels, followed a similar pattern during the 48 hours after injection in all 3 phases of the cycle. Prolonged follicular phases and anovulation were the result of the gonadotropin surge induced by LRF agonist in EFP. 3/4 subjects in the LFP showed evidence of ovulation in response to the same dose of agonist. This study demonstrates that this LRF agonist is a potent agonist of LRF in human subjects, and is approximately 144 times more potent than the decapeptide LRF.
 ...
PMID:Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle. 38 1